Houston-based PolyVascular — a MedTech Innovator accelerator participant in 2020 — develops a first-of-its-kind heart valve. The potentially transformative, non-surgical valve could treat young children suffering from congenital heart disease.
New York-based CobiCure, a non-profit pediatric initiative, aims to provide strategic support and resources in addition to the funding. The initiative seeks to further advance the development of the novel polymer heart valve toward human clinical readiness.
According to a news release, the companies hope to accelerate potentially life-saving technology for children born with congenital heart defects.
“CobiCure’s mission, strategic ecosystem, and critical resources are a perfect match for helping PolyVascular realize their goal of eliminating invasive surgeries in children with congenital heart disease,” said Emma Moran, director of strategy & development at CobiCure. “Our commitment to supporting life-changing medical devices like PolyVascular’s will fill gaps in pediatric medtech and we look forward to the positive impact it could have on children’s lives.”
The resources and funding adds to $3.5 million in grants previously secured by PolyVascular. Those came from sources including the National Institutes of Health (NIH) Small Business Innovation Research (SBIR).
“CobiCure’s mission and vision were a perfect match for PolyVascular’s goal to eliminate repeat surgeries in children with congenital heart disease,” said Dr. Will Clifton, PolyVascular COO. “With this partnership, we are one step closer to reaching this vulnerable population and improving their quality of life.”
More about PolyVascular
PolyVascular featured in Medical Design & Outsourcing’s list of 20 medical device startups you need to know in 2020.
Founded in 2014, the company develops polymeric transcatheter valves to combat congenital heart disease. It designed its PTVs for easy manufacturing in pediatric and adult sizes. They also feature the capability to expand and accommodate growth of children. That reduces the need for repeat open-heart surgeries.
The company’s timeline for bringing its valve to market includes the aim to complete its animal study this year, according to its website. PolyVascular earmarked first-in-human efforts for 2025, followed by completed enrollment in 2026. The company ultimately aims to garner FDA approval in 2028.
